168 related articles for article (PubMed ID: 31140829)
21. Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer.
Yang H; Yu M; Zhong S; You Y; Feng F
J Ovarian Res; 2022 Jan; 15(1):18. PubMed ID: 35093146
[TBL] [Abstract][Full Text] [Related]
22. Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.
Zhang L; Zhang X; Fan S; Zhang Z
Medicine (Baltimore); 2019 Nov; 98(44):e17803. PubMed ID: 31689861
[TBL] [Abstract][Full Text] [Related]
23. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
24. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
25. Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.
Tan J; Song C; Wang D; Hu Y; Liu D; Ma D; Gao Q
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33891016
[TBL] [Abstract][Full Text] [Related]
26. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
Slaughter K; Holman LL; Thomas EL; Gunderson CC; Lauer JK; Ding K; McMeekin DS; Moore KM
Gynecol Oncol; 2016 Aug; 142(2):225-30. PubMed ID: 27208536
[TBL] [Abstract][Full Text] [Related]
27. Expression and clinical significance of methyl-CpG binding domain protein 2 in high-grade serous ovarian cancer.
Gong W; Ni M; Chen Z; Zheng Z
Oncol Lett; 2020 Sep; 20(3):2749-2756. PubMed ID: 32782591
[TBL] [Abstract][Full Text] [Related]
28. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
29. Methylomic Signatures of High Grade Serous Ovarian Cancer.
Cardenas H; Fang F; Jiang G; Perkins SM; Zhang C; Emerson RE; Hutchins G; Keer HN; Liu Y; Matei D; Nephew K
Epigenetics; 2021 Nov; 16(11):1201-1216. PubMed ID: 33289590
[TBL] [Abstract][Full Text] [Related]
30. 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
Weigert M; Cui XL; West-Szymanski D; Yu X; Bilecz AJ; Zhang Z; Dhir R; Kehoe M; Zhang W; He C; Lengyel E
Gynecol Oncol; 2024 Mar; 182():82-90. PubMed ID: 38262243
[TBL] [Abstract][Full Text] [Related]
31. CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1.
Luo X; Wei Q; Jiang X; Chen N; Zuo X; Zhao H; Liu Y; Liu X; Xie L; Yang Y; Liu T; Yi P; Xu J
Cell Death Dis; 2024 Jun; 15(6):432. PubMed ID: 38898019
[TBL] [Abstract][Full Text] [Related]
32. A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
Song J; Zhang W; Wang S; Liu K; Song F; Ran L
Int J Oncol; 2018 Aug; 53(2):866-876. PubMed ID: 29749482
[TBL] [Abstract][Full Text] [Related]
33. Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
Scurry J; van Zyl B; Gulliver D; Otton G; Jaaback K; Lombard J; Vilain RE; Bowden NA
Gynecol Oncol; 2018 Nov; 151(2):306-310. PubMed ID: 30194007
[TBL] [Abstract][Full Text] [Related]
34. The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer.
Zheng ZG; Xu H; Suo SS; Xu XL; Ni MW; Gu LH; Chen W; Wang LY; Zhao Y; Tian B; Hua YJ
Sci Rep; 2016 May; 6():26093. PubMed ID: 27193186
[TBL] [Abstract][Full Text] [Related]
35. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
36. Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer.
Yong W; Yu D; Jun Z; Yachen D; Weiwei W; Midie X; Xingzhu J; Xiaohua W
Cell Death Dis; 2018 Aug; 9(9):861. PubMed ID: 30154460
[TBL] [Abstract][Full Text] [Related]
37. Long Non-coding RNA
Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
39. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
[TBL] [Abstract][Full Text] [Related]
40. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
